TaBriX is a UK-based biotech startup company developing innovative therapies for difficult to treat & life-endangering infections in chronic patients. Our lead asset is a first-in-class, broad-spectrum, anti-virulent small molecule designed to be delivered orally, to treat non-tuberculous mycobacteria (NTMs) in patients with cystic fibrosis and bronchiectasis.